Get the Stockscreener App
3.77
0.53%
-0.02
Generation Bio Co stock is currently priced at $3.77, with a 24-hour trading volume of 115.95K.
It has seen a -0.53% decreased in the last 24 hours and a +20.45% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $3.93 pivot point. If it approaches the $3.52 support level, significant changes may occur.
Previous Close:
$3.79
Open:
$3.7
24h Volume:
115.95K
Market Cap:
$250.66M
Revenue:
-
Net Income/Loss:
$-126.61M
P/E Ratio:
-1.8125
EPS:
-2.08
Net Cash Flow:
$-60.14M
1W Performance:
+15.64%
1M Performance:
+20.45%
6M Performance:
+236.61%
1Y Performance:
-16.96%
1D Range:
$3.6612
$3.98
52W Range:
$0.86
$6.98
Generation Bio Co Stock (GBIO) Company Profile
Name
Generation Bio Co
Sector
Industry
Phone
857 529 5908
Address
301 Binney Street, Cambridge
Generation Bio Co Stock (GBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-08-22 | Initiated | Canaccord Genuity | Buy |
| Dec-14-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-08-21 | Initiated | JMP Securities | Mkt Outperform |
| Feb-24-21 | Initiated | William Blair | Outperform |
| Feb-18-21 | Initiated | Needham | Buy |
| Jul-07-20 | Initiated | Cowen | Outperform |
| Jul-07-20 | Initiated | JP Morgan | Overweight |
| Jul-07-20 | Initiated | Jefferies | Buy |
| Jul-07-20 | Initiated | Wedbush | Outperform |
View All
Generation Bio Co Stock (GBIO) Latest News
Generation Bio Co. Forecasted to Post Q2 2024 Earnings of ($0.21) Per Share (NASDAQ:GBIO) - Defense World
Defense World
Equities Analysts Set Expectations for Generation Bio Co.'s Q2 2024 Earnings (NASDAQ:GBIO) - MarketBeat
MarketBeat
Generation Bio (NASDAQ:GBIO) Receives “Outperform” Rating from Wedbush - Defense World
Defense World
Generation Bio's (GBIO) “Buy” Rating Reaffirmed at Needham & Company LLC - Defense World
Defense World
Generation Bio Co. Forecasted to Post Q1 2025 Earnings of ($0.12) Per Share (NASDAQ:GBIO) - Defense World
Defense World
Wedbush Weighs in on Generation Bio Co.'s Q1 2025 Earnings (NASDAQ:GBIO) - MarketBeat
MarketBeat
Generation Bio Co Stock (GBIO) Financials Data
Generation Bio Co (GBIO) Net Income 2024
GBIO net income (TTM) was -$126.61 million for the quarter ending December 31, 2023, a +7.34% increase year-over-year.
Generation Bio Co (GBIO) Cash Flow 2024
GBIO recorded a free cash flow (TTM) of -$60.14 million for the quarter ending December 31, 2023, a +45.94% increase year-over-year.
Generation Bio Co (GBIO) Earnings per Share 2024
GBIO earnings per share (TTM) was -$1.96 for the quarter ending December 31, 2023, a +16.60% growth year-over-year.
About Generation Bio Co
Generation Bio Co., a genetic medicines company, develops gene therapies for the treatment of rare and prevalent diseases. The company is developing a portfolio of eight programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was founded in 2016 and is headquartered in Cambridge, Massachusetts.
4.27%
2.59%
Cap:
|
Volume (24h):